Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes.

We have studied 35 single nucleotide polymorphisms (SNPs) in the interferon (IFN) pathway to determine their contribution to multiple sclerosis (MS) and hepatitis C virus (HCV) infection. A total of 182 patients with MS, 103 patients with chronic hepatitis C, and 118 control subjects were enrolled in the study. Of the 35 SNPs studied, 3 were in IFN-alpha receptor (IFNAR-1), 10 in IFN-alpha/beta receptor (IFNAR-2), 9 in Stat1, 5 in Stat2, and 8 in IFN regulatory factor-1 (IRF-1). Compared to controls, Stat1 gene polymorphisms were significantly more frequent in MS patients (rs# 2066802 OR = 7.46, 95% CI = 2.22-25.10; rs# 1547550 OR = 1.69, 95% CI = 1.01-2.81) and in HCV patients (rs# 2066802 OR = 5.95, 95% CI = 1.55-22.81; rs# 1547550 OR = 2.30, 95% CI = 1.24-4.24). Also one IRF-1 gene SNP was associated with MS (rs# 2070721 OR = 2.05, 95% CI = 1.03-4.09), and four IRF-1 gene SNPs were associated with HCV infection (rs# 2070721 OR = 2.59, 95% CI = 1.23-5.43; rs# 2070723 OR = 4.8, 95% CI = 1.26-18.20; rs# 2070728 OR = 9.81, 95% CI = 1.21-79.4; rs# 2070729 OR = 3.6, 95% CI = 1.23-10.48; rs# 839 OR = 4.67, 95%CI = 1.29-16.87). Characteristic nucleotide combinations on single chromosomes (haplotype) generated block structures, including SNPs, that differed between patients and controls. Using a permutation test to detect differences in haplotype distribution between groups, the CCATTGA and the CCGAA haplotypes in the IRF-1 gene were more frequent in MS (p = 0.03) and in HCV patients (p = 0.001) than in controls. In conclusion, our data show that genetic variants in the IRF-1 and Stat1 genes of the IFN pathway are associated with MS and HCV infection.

[1]  Guoping Zhao,et al.  Current research status of immunology in the genomic era , 2009, Science in China Series C: Life Sciences.

[2]  L. Scott,et al.  Interferon-β-1b , 2004 .

[3]  R. Balabanov,et al.  STAT1/IRF‐1 signaling pathway mediates the injurious effect of interferon‐gamma on oligodendrocyte progenitor cells , 2010, Glia.

[4]  G. Stewart,et al.  Identification of 11 novel and common single nucleotide polymorphisms in the interleukin-7 receptor-α gene and their associations with multiple sclerosis , 2003, European Journal of Human Genetics.

[5]  M. Daly,et al.  A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.

[6]  C. Samuel,et al.  Antiviral Actions of Interferons , 2001, Clinical Microbiology Reviews.

[7]  Arto Mannermaa,et al.  Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women , 2005, European Journal of Human Genetics.

[8]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[9]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[10]  N. Saitou,et al.  Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. , 2003, Human molecular genetics.

[11]  N. Enomoto,et al.  Regulation of Hepatitis C Virus Replication by Interferon Regulatory Factor 1 , 2004, Journal of Virology.

[12]  X. Montalban,et al.  Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis , 2003, Genes and Immunity.

[13]  B. Weinshenker,et al.  CD95 polymorphisms are associated with susceptibility to MS in women A population-based study of CD95 and CD95L in MS , 2004, Journal of Neuroimmunology.

[14]  A. Reder,et al.  Therapeutic role of beta-interferons in multiple sclerosis. , 2006, Pharmacology & therapeutics.

[15]  H. Bickeböller,et al.  Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection , 2006, European journal of gastroenterology & hepatology.

[16]  M. Ingelman-Sundberg,et al.  3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. , 2006, Biochemical and biophysical research communications.

[17]  T. Ball,et al.  Polymorphisms in IRF-1 associated with resistance to HIV-1 infection in highly exposed uninfected Kenyan sex workers , 2007, AIDS.

[18]  Martin Farrall,et al.  Genetic susceptibility to coronary artery disease: from promise to progress , 2006, Nature Reviews Genetics.

[19]  T. Taniguchi,et al.  The interferon-α/β system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors , 2002 .

[20]  Murali Ramanathan,et al.  Genomic Effects of IFN-β in Multiple Sclerosis Patients 1 , 2003, The Journal of Immunology.

[21]  D. Bell,et al.  Single nucleotide polymorphism in transcriptional regulatory regions and expression of environmentally responsive genes. , 2005, Toxicology and applied pharmacology.

[22]  Edward A Belongia,et al.  National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. , 2009, Annals of internal medicine.

[23]  T. Olsson,et al.  Lack of association between the interferon regulatory factor-1 (IRF1) locus at 5q31.1 and multiple sclerosis in Germany, Northern Italy, Sardinia and Sweden , 2000, Genes and Immunity.

[24]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[25]  A. Goris,et al.  Polymorphisms in the interleukin‐4 and IL‐4 receptor genes and multiple sclerosis: a study in Spanish‐Basque, Northern Irish and Belgian populations , 2005, International journal of immunogenetics.

[26]  M. David,et al.  Impaired Development of CD4+ CD25+ Regulatory T Cells in the Absence of STAT1 , 2004, The Journal of experimental medicine.

[27]  E. Urcelay,et al.  Role of interleukin 4 in Spanish multiple sclerosis patients , 2005, Journal of Neuroimmunology.

[28]  M. Alarcón-Riquelme.  The genetics of systemic lupus erythematosus: understanding how SNPs confer disease susceptibility , 2006, Springer Seminars in Immunopathology.

[29]  A. L. Petraglia,et al.  Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1 , 2002, Journal of Neuroimmunology.

[30]  H. Saito,et al.  The detection of IRF-1 promoter polymorphisms and their possible contribution to T helper 1 response in chronic hepatitis C. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[31]  C. Lucchinetti,et al.  Multiple Sclerosis: Current Pathophysiological Concepts , 2001, Laboratory Investigation.

[32]  Fuencisla Matesanz,et al.  IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response , 2005, Journal of Neuroimmunology.

[33]  J Cohen,et al.  The Scientific Challenge of Hepatitis C , 1999, Science.

[34]  E. Schmidt,et al.  Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. , 2005, Gastroenterology.

[35]  G. McDonnell,et al.  An evaluation of interleukin genes fails to identify clear susceptibility loci for multiple sclerosis , 2000, Journal of the Neurological Sciences.